Gan & Lee Pharmaceuticals: Obesity trials

The registry lists 11 Obesity studies with Gan & Lee Pharmaceuticals as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 1 5Phase 2 2Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study ParticipantsRecruitingNCT07784699Phase 1
• Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) TherapyNot yet recruitingNCT07493057Phase 3
• Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossRecruitingNCT07292441Phase 3
• Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight SubjectsRecruitingNCT07150975Phase 3
• Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver FunctionRecruitingNCT07144098Phase 1
• Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal FunctionRecruitingNCT07141030Phase 1
• Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 InjectionRecruitingNCT07128888Phase 1
• The Study of [14C] GZR18CompletedNCT07119450Phase 1
• Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight ParticipantsCompletedNCT06737042Phase 2
• A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsActive, not recruitingNCT06728124Phase 3
• A Study of GZR18 Injection in Obese/Overweight PatientsCompletedNCT06256562Phase 2